(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
Tzrifin base exhibition reveals Hamas and Hezbollah arms, showing structure behind attacks- Tablets: Upgrade Your Understanding Experience
- Cocaine, caffeine, painkillers consumed by sharks in Bahamas, study finds
- Bother Control Administrations for 2024: Decide for Your Home
- 10 Hints for a Fruitful New employee screening
- Foot fossil discovery could reshape human evolutionary history
- The 10 Most Progressive Logical Disclosures
- 7 Fast Approaches to Let loose Space on Your Telephone in a flash
- The Way to Fruitful Weight reduction: Individual Wellbeing Excursions
